Tonix Pharmaceuticals to Present at the Summer 2024 Virtual Investor Summit
Tonix Pharmaceuticals (Nasdaq: TNXP) announced that CEO Seth Lederman will present at the Summer 2024 Virtual Investor Summit on August 20, 2024, at 11:00 a.m. ET. The presentation will be available via webcast on the company's website. Tonix is a fully-integrated biopharmaceutical company with marketed products and a development pipeline focused on central nervous system (CNS) disorders.
Key highlights include:
- Plans to submit a New Drug Application (NDA) for TNX-102 SL for fibromyalgia management in the second half of 2024
- FDA Fast Track designation for TNX-102 SL
- Development of TNX-1300 for cocaine intoxication with Breakthrough Therapy designation
- Immunology portfolio including TNX-1500 for organ transplant rejection and autoimmune diseases
- Commercial products: Zembrace SymTouch and Tosymra for acute migraine treatment
Tonix Pharmaceuticals (Nasdaq: TNXP) ha annunciato che il CEO Seth Lederman presenterà al Summer 2024 Virtual Investor Summit il 20 agosto 2024, alle 11:00 ET. La presentazione sarà disponibile in diretta streaming sul sito dell'azienda. Tonix è una azienda biofarmaceutica completamente integrata con prodotti commercializzati e un portafoglio di sviluppo focalizzato su disturbi del sistema nervoso centrale (SNC).
I punti salienti includono:
- Piani per presentare una Nuova Richiesta di Farmaco (NDA) per TNX-102 SL per la gestione della fibromialgia nella seconda metà del 2024
- Designazione FDA Fast Track per TNX-102 SL
- Sviluppo di TNX-1300 per intossicazione da cocaina con designazione di Terapia Innovativa
- Portafoglio di immunologia che include TNX-1500 per rigetto di trapianto d'organo e malattie autoimmuni
- Prodotti commerciali: Zembrace SymTouch e Tosymra per il trattamento dell'emicrania acuta
Tonix Pharmaceuticals (Nasdaq: TNXP) anunció que el CEO Seth Lederman presentará en el Summer 2024 Virtual Investor Summit el 20 de agosto de 2024, a las 11:00 a.m. ET. La presentación estará disponible a través de una transmisión en vivo en el sitio web de la compañía. Tonix es una empresa biofarmacéutica completamente integrada con productos comercializados y un pipeline de desarrollo centrado en trastornos del sistema nervioso central (SNC).
Los aspectos más destacados incluyen:
- Planes para presentar una Nueva Solicitud de Medicamento (NDA) para TNX-102 SL para el manejo de la fibromialgia en la segunda mitad de 2024
- Designación Fast Track de la FDA para TNX-102 SL
- Desarrollo de TNX-1300 para la intoxicación por cocaína con designación de Terapia Innovadora
- Portafolio de inmunología que incluye TNX-1500 para el rechazo de trasplante de órganos y enfermedades autoinmunes
- Productos comerciales: Zembrace SymTouch y Tosymra para el tratamiento de la migraña aguda
Tonix Pharmaceuticals (Nasdaq: TNXP)는 CEO Seth Lederman이 2024년 8월 20일 오전 11시(동부 표준시)에 2024 여름 가상 투자 정상 회담에서 발표할 것이라고 발표했습니다. 발표는 회사 웹사이트를 통해 웹캐스트로 제공될 것입니다. Tonix는 완전 통합 바이오제약 회사로, 시장에 출시된 제품과 중추 신경계(CNS) 장애에 중점을 둔 개발 파이프라인을 보유하고 있습니다.
주요 하이라이트:
- 2024년 하반기에 섬유근육통 관리용 TNX-102 SL에 대한 신약 신청(NDA) 제출 계획
- TNX-102 SL의 FDA 신속 승인 지정
- 획기적 치료 지정이 있는 코카인 중독을 위한 TNX-1300 개발
- 장기 이식을 위한 TNX-1500 및 자가면역 질환을 포함한 면역학 포트폴리오
- 상업적 제품: 급성 편두통 치료를 위한 Zembrace SymTouch 및 Tosymra
Tonix Pharmaceuticals (Nasdaq: TNXP) a annoncé que le PDG Seth Lederman présentera lors du Summer 2024 Virtual Investor Summit le 20 août 2024 à 11h00 ET. La présentation sera disponible en webcast sur le site de l'entreprise. Tonix est une entreprise biopharmaceutique entièrement intégrée avec des produits commercialisés et un pipeline de développement axé sur les troubles du système nerveux central (SNC).
Les points clés incluent :
- Plans pour soumettre une demande de nouveau médicament (NDA) pour TNX-102 SL pour la gestion de la fibromyalgie dans la seconde moitié de 2024
- Designation Fast Track de la FDA pour TNX-102 SL
- Développement de TNX-1300 pour l'intoxication à la cocaïne avec désignation de thérapie révolutionnaire
- Portefeuille en immunologie comprenant TNX-1500 pour le rejet d'organe et les maladies auto-immunes
- Produits commerciaux : Zembrace SymTouch et Tosymra pour le traitement de la migraine aiguë
Tonix Pharmaceuticals (Nasdaq: TNXP) gab bekannt, dass CEO Seth Lederman am Summer 2024 Virtual Investor Summit am 20. August 2024 um 11:00 Uhr ET präsentieren wird. Die Präsentation wird über einen Webcast auf der Website des Unternehmens verfügbar sein. Tonix ist ein vollständig integriertes biopharmazeutisches Unternehmen mit auf den Markt gebrachten Produkten und einer Entwicklungspipeline, die sich auf Störungen des zentralen Nervensystems (ZNS) konzentriert.
Wichtige Highlights:
- Pläne zur Einreichung eines Antrags auf ein neues Medikament (NDA) für TNX-102 SL zur Behandlung von Fibromyalgie in der zweiten Hälfte von 2024
- FDA Fast Track-Einstufung für TNX-102 SL
- Entwicklung von TNX-1300 zur Behandlung von Kokainintoxikation mit dem Status einer bahnbrechenden Therapie
- Immunologie-Portfolio einschließlich TNX-1500 für Organtransplantationsabstoßung und Autoimmunerkrankungen
- Kommerzielle Produkte: Zembrace SymTouch und Tosymra zur Behandlung von akuten Migräneanfällen
- None.
- None.
CHATHAM, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will present at the Summer 2024 Virtual Investor Summit on Tuesday, August 20, 2024, at 11:00 a.m. ET.
Investors interested in arranging a meeting with the Company’s management virtually during the conference should contact the Investor Summit conference coordinator. A webcast of the presentation will be available under the IR Events tab of the Tonix website at www.tonixpharma.com.
Tonix Pharmaceuticals Holding Corp.*
Tonix is a fully-integrated biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for TNX-102 SL, a product candidate for which two statistically significant Phase 3 studies have been completed for the management of fibromyalgia. The FDA has granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction. Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has Breakthrough Therapy designation. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.
*Tonix’s product development candidates are investigational new drugs or biologics and have not been approved for any indication.
Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.
This press release and further information about Tonix can be found at www.tonixpharma.com.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
Investor Contact
Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 904-8182
Peter Vozzo
ICR Westwicke
peter.vozzo@westwicke.com
(443) 213-0505
Media Contact
Katie Dodge
LaVoieHealthScience
kdodge@lavoiehealthscience.com
(978) 360-3151
FAQ
When is Tonix Pharmaceuticals (TNXP) presenting at the Summer 2024 Virtual Investor Summit?
What is the main focus of Tonix Pharmaceuticals' (TNXP) development portfolio?
When does Tonix Pharmaceuticals (TNXP) plan to submit a New Drug Application for TNX-102 SL?
What designation has the FDA granted to Tonix Pharmaceuticals' (TNXP) TNX-102 SL?